Interpace Biosciences, Inc.

OTCPK:IDXG Rapport sur les actions

Capitalisation boursière : US$6.2m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Interpace Biosciences Bilan de santé

Santé financière contrôle des critères 2/6

Interpace Biosciences has a total shareholder equity of $-12.5M and total debt of $6.8M, which brings its debt-to-equity ratio to -54.3%. Its total assets and total liabilities are $13.0M and $25.5M respectively. Interpace Biosciences's EBIT is $4.4M making its interest coverage ratio 5. It has cash and short-term investments of $2.0M.

Informations clés

-54.3%

Ratio d'endettement

US$6.78m

Dette

Ratio de couverture des intérêts5x
Argent liquideUS$2.02m
Fonds propres-US$12.49m
Total du passifUS$25.46m
Total des actifsUS$12.97m

Mises à jour récentes de la santé financière

Recent updates

Interspace Biosciences trades high, appoints new finance chief

Feb 04

Interpace signs licensing agreement for monoclonal antibody platform Das-1

Feb 01

Analyse de la situation financière

Passif à court terme: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Passif à long terme: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Historique et analyse du ratio d'endettement

Niveau d'endettement: IDXG has negative shareholder equity, which is a more serious situation than a high debt level.

Réduire la dette: IDXG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Couverture de la dette: IDXG's debt is well covered by operating cash flow (52.9%).

Couverture des intérêts: IDXG's interest payments on its debt are well covered by EBIT (5x coverage).


Bilan


Découvrir des entreprises saines